JAJavier Merino Alonso

Javier Merino Alonso

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Javier Merino Alonso has a total of 48 co-authors. Here are the top co-authors by number of shared publications:

  • P Joy Carmona

    Hospital Universitario Nuestra Señora de Candelaria, Servicio de Farmacia, Santa Cruz de Tenerife, Spain

    2 shared publications
  • A Martin López

    Hospital Universitario Nuestra Señora de Candelaria, Servicio de Farmacia, Santa Cruz de Tenerife, Spain

    1 shared publication
  • Amelia Sánchez-Guerrero

    L 12 Hospital Puerta de Hierro, Pharmacy, Madrid, Spain

    1 shared publication
  • Amparo Burgos-SanJosé

    D 4 Hospital General de Alicante, Pharmacy, Alicante, Spain

    1 shared publication
  • Ana Cabello Rodríguez

    Hospital Universitario Nuestra Señora de Candelaria

    1 shared publication
  • Ana Reyes Santana

    Servicio de Farmacia Hospitalaria, Hospital Universitario Nuestra Señora de Candelaria de Tenerife, Santa Cruz de Tenerife, España

    1 shared publication

Latest Publications

  • Open Access

    5PSQ-098 Safety and persistence of anti-fibrotic drugs in interstitial lung diseases

    by P Joy Carmona, J Gonzalez Chavez, M Suarez Gonzalez, P Diaz Ruiz, J Merino Alonso

    Background and Importance Interstitial lung diseases (ILD) is a group of rare diseases with bad prognosis, being Idiopathic pulmonary fibrosis (IPF) the most frequent of them. They can be treated with antifibrotic drugs: nintedanib or pirfenidone. However, these drugs have a high rate of adverse effects, which has a significant impact on treatment persistence. Aim and Objectives To analyse the safety of pirfenidone and nintedanib in patients with ILD as well as treatment’s persistence, in a third-level hospital. Material and Methods Retrospective observational study of patients with ILD treated with antifibrotic drugs from January 2016 to August 2022. Variables: sex, age, drug, duration of antifibrotic treatment, associated drug, switch to another antifibrotic drug, side effects, discontinuations, deaths. Information was collected from the hospital’s information systems. Results 66 patients, 67% men, mean age 67 (47–86). 44 patients with nintedanib: 23 IPF, 14 progressive pulmonary fibrosis (PPF), 2 ILD associated with systemic sclerosis, 4 fibroemphysema and 1 ILD not classified. 5 of them were treated with an associated immunosuppressive drug: mycophenolate mofetil. 12 patients needed a dose reduction due to gastrointestinal effects: 100% diarrhea, 80% nausea. 1 patient needed temporary discontinuation due to increased transaminases, which were finally stabilised, being able to return to a higher dose. 2 patients needed discontinuation of treatment due to bleeding: 1 patient was on antiplatelet therapy and the other had a background of epistaxis. These two patients switched to pirfenidone. 22 patients with pirfenidone: all of them IPF. 2 patients needed dose reduction due to diarrhoea and 2 needed treatment discontinuation due to severe sunburns. These patients switched to nintedanib. Persistence until progression 18 months with nintedanib and 24 months with pirfenidone. 8 patients died during treatment, 4 of them because of COVID-19 infection. Conclusion and Relevance Thanks to a close follow-up in patients with ILD, it is possible to modify the dose and to achieve greater tolerance to treatments. The pandemic affected negatively during the year 2020, not only because of the impossibility of receiving medical appointments, but also due to the acceleration of their death. The rapid establishment of anti-fibrotic treatment and the adequate control of adverse effects are the key for this type of patients. Conflict of Interest No conflict of interest

  • Open Access

    5PSQ-092 Pharmacovigilance of biological therapies from the outpatient department

    by Ki Álvarez Tosco, P Díaz Ruíz, J González Chávez, M Suárez González, A Martin López, P Joy Carmona, Cy Perez Martin, J Merino Alonso

    Background and Importance Pharmacovigilance has an essential role in monitoring outpatient treatments. As healthcare professionals we have the responsibility to report suspected adverse drug reactions (ADRs), so these data can be analysed by pharmacovigilance centres to determine the causality of possible unknown risks or changes in the severity and frequency of those already known. In the last decade, the rise of biological therapies as standard treatment in a huge array of pathologies in outpatient practices has led us to focus our project on them. Aim and Objectives Analyse suspected ADRs reported to the National Pharmacovigilance System of the Agency of Medicines and Health Products (AMHPS), from the outpatient department in a central Hospital Pharmacy. Material and Methods Single-centre observational retrospective study of suspected adverse reactions reported over a three-month period [July 2022 – September 2022]. The following data were collected: age, sex, treatment, indication, date of initiation, ADRs type and duration. Results were compared with the AMHPS National database, which is updated every 3 months. Results In these months, we reported seven suspected ADRs. Most of them were reported in women(85,8%), with a mean age of 49,6 years(32–64). The biological therapies suspected of triggering ADRs were adalimumab, sarilumab, etanercept, abatacept, erenumab and galcanezumab. The adverse reactions reported were mostly related to the presence of infections(42,8%), followed by muscle disorders(28,6%), nausea(14,3%) and neutropenia(14,3%). Among the biological therapies used, the one associated with the highest number of notifications was sarilumab(28,6%) and the most frequent indication was rheumatoid arthritis(57,14%). Conclusion and Relevance Comparing the results with the AMHPS database, in our population we observe a greater number of notifications for sarilumab, being the one with the fewest national notifications, probably related to its recent authorisation and not being used in first-line treatments. On the other hand, in the overall number of national ADRs notifications, infections are not the most frequent ADR, being in the first place musculoskeletal and gastrointestinal disorders. It is important to be aware of the role of pharmacists and all healthcare professionals in contributing to the detection of ADRs. Collecting this data and taking a global view of it by healthcare institutions allows to improve safety in outpatient treatments. Conflict of Interest No conflict of interest

  • Open Access

    Actividad de Erwinia-asparraginasa tras reacción anafiláctica a Peg-asparraginasa

    by Maria Micaela Viña Romero, Sara García Gil, Gloria Julia Nazco Casariego, Javier Merino Alonso, Fernando Gutiérrez Nicolás

  • The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use

    by Julio Martinez-Cutillas, Carme Alerany-Pardo, Joaquín Borrás-Blasco, Antonio Broto-Sumalla, Amparo Burgos-SanJosé, Consuelo Climent-Bolta, Vicente Escudero-Vilaplana, María Anunciación Fernández-Fuente, Mónica Ferrit-Martin, Pilar Gómez-Germá, et al.

    Rheumatoid arthritis (AR), psoriatic arthritis (PSA) and ankylosing spondylitis (AS) are autoimmune systemic diseases characterized by inflammation, pain and joint degeneration. The objective of this study is to evaluate, under the actual conditions of use, dosing patterns of adalimumab, etanercept, golimumab and infliximab in these pathologies, and compare them with the label regimens recommended, as well as evaluating the financial implications of these regimen modifications. The study population included all adult patients diagnosed with RA, PSA or AS who had been treated with adalimumab, etanercept, golimumab and infliximab for at least 6 months between 1 January 2011 and 31 December 2013. The main variable of this study was to assess the dose dispensed for drugs administered subcutaneously and the dose prepared/administered for drugs administered intravenously, and the annual costs of the treatment. A total of 5,428 episodes were included. The mean weekly dose was lower than the standard dose in the three pathologies studied in the patients treated with adalimumab and etanercept (84.3% vs 81.2% for RA, 85.0% vs 78.0% for PSA and 87.8% vs 81.6% for AS). The drugs with highest dose optimization in RA are etanercept (46.3%) followed by adalimumab (46%); however, the highest percentage of patients with major dose optimization corresponds to etanercept (11.6%). Both in the PA and the AS group, we also observed that etanercept is the drug more optimized, corresponding to 53.9 and 43% of patients, respectively. By contrast, 48.5% of patients with RA treated with infliximab required dose intensification; however, infliximab dose intensification in PSA and AS is not so pronounced. The practice of optimization of dose regimens in patients with rheumatic diseases under treatment with anti-TNFα is spreading among professionals, resulting in annual cost reduction in the treatment of rheumatic arthropathies. However, long term follow-up will be necessary to assess the influence of this optimization on health outcomes.


  • Open Access

    Sildenafilo oral para la hipertensión pulmonar en neonatos

    by F. Gutiérrez Nicolás, M.M. Viña Romero, P. González Carretero, J. Merino Alonso

  • Open Access

    Reutilización de citostáticos en una unidad centralizada de mezclas

    by S. Ramos Linares, J. Merino Alonso, N. Román González, E. Tévar Alfonso, P. Díaz Ruíz, M. Gorchs Molist


  • Severe ifosfamide-induced neurotoxicity: a case report

    by Sara Ramos Linares, Joaquín Breña Atienza, Matilde Cháfer Rudilla, Pablo Ríos Rull, Ana Cabello Rodríguez, Javier Merino Alonso

    Introduction Ifosfamide is an alkylating agent used in the treatment of several neoplasias. Ifosfamide metabolites accumulation can produce neurotoxicity, which sometimes manifests as a severe clinical picture. Case description We describe the case of a male with a mixed cellularity subtype classical Hodgkin’s lymphoma, treated with ifosfamide after other chemotherapy drugs failure. After the first Ifosfamide cycle, the patient showed severe neurological toxicity that resolved 3 weeks later with supportive therapy. Discussion Among the risk factors described in the literature, our patient had previously received cysplatin chemotherapy, had low albumin serum levels, and had received ifosfamide as a rapid intravenous infusion. The management of the neurotoxicity is symptomatic although some drugs, like methylene blue and albumin, have also been used. Conclusion This case highlights that clinicians should be aware of the possibility of severe neurological toxicity after the administration of ifosfamide and may control the risk factors associated.


  • Recomendaciones sobre el tratamiento farmacológico perioperatorio

    by Matilde Cháfer Rudilla, J. Pablo Domínguez Rodríguez, Ana Reyes Santana, Marta Gorchs Molist, María de Los Ángeles Ocaña Gómez, José Antonio Martín Conde, Javier Merino Alonso